Treatment of Mantle Cell Lymphoma

Initial Assessment and Stratification

The European Society for Medical Oncology recommends using the Mantle Cell Lymphoma International Prognostic Index (MIPI-c) for risk stratification, incorporating ECOG performance status, age, leukocyte count, LDH, and Ki-67 proliferation index 3
SOX11 negativity may help identify indolent cases, while additional TP53 mutations can cause aggressive clinical evolution even in otherwise indolent-appearing disease 3

For asymptomatic patients with indolent features, a "watch and wait" approach under close observation is appropriate, as recommended by the European Society for Medical Oncology 4, 5
SOX11 negativity with hypermutated IGHV helps confirm truly indolent disease, according to the European Hematology Association 5

For patients with limited non-bulky stages I-II, a shortened conventional chemotherapy induction followed by consolidation radiotherapy is recommended by the European Society for Medical Oncology 4, 6
In stage I-II patients with large tumor burden or adverse prognostic features, systemic therapy as indicated for advanced stages should be applied, as suggested by the National Comprehensive Cancer Network 4, 6

Intensive induction with cytarabine-containing regimens followed by ASCT is the standard of care for younger fit patients, according to the American Society of Clinical Oncology 1, 2
Options include R-CHOP/R-DHAP and R-hyperCVAD/MTX-Ara-C, as recommended by the European Society for Medical Oncology 1, 7
A randomized trial confirmed that cytarabine-containing induction achieves significantly improved median time to treatment failure, as reported by the European Society for Medical Oncology 1

Less intensive immunochemotherapy regimens are recommended for elderly patients who are not candidates for intensive therapy, according to the International Society of Geriatric Oncology 1, 2
Preferred regimens include bendamustine-rituximab and R-CHOP, as suggested by the European Society for Medical Oncology 2

Rituximab maintenance significantly improves progression-free survival and overall survival after R-CHOP and should be administered, as recommended by the American Society of Clinical Oncology 1, 2
Maintenance rituximab is given every 2 months for up to 3 years following induction therapy, according to the European Society for Medical Oncology 1, 2

Treatment approach depends on the duration of prior response, patient fitness, and prior therapies, as suggested by the National Comprehensive Cancer Network 7
For late relapses, repeating the previous effective therapy may be considered, according to the European Society for Medical Oncology 1
For early relapses or refractory disease, targeted approaches are recommended, including ibrutinib, lenalidomide, and temsirolimus, as reported by the American Society of Clinical Oncology 1, 7